Zymeworks halts development of cancer drug after trial setback
02/09/2025 11:06
Sept 2 (Reuters) - Zymeworks ZYME.O said on Tuesday it will stop developing its experimental cancer drug after early-stage trial results showed the treatment was unlikely to meet the company's goals as a standalone therapy. (Reporting by Kamal Choudhury in Bengaluru; Editing by Krishna Chandra Eluri) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Zymeworks
See all newsBrief: Zymeworks Presents New Phase 1 Data For Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191
US STOCKS ON THE MOVE-Huron Consulting, RingCentral, Selective Insurance
U.S. STOCKS ON THE MOVE-Huron Consulting, Crown Castle, Bloom Energy
US STOCKS ON THE MOVE-Booz Allen Hamilton, SLB, Deckers Outdoor
US STOCKS ON THE MOVE-American Express, Gorman-Rupp, Moderna